Fixing Psychiatric Research At A University
By Ed Silverman,
Pharmalot
| 03. 20. 2013
[Op-Ed]
Over the past few years, University of Minnesota bioethicist Carl Elliott has explored a complicated and increasingly controversial episode over a clinical trial and a suicide. The saga has involved researchers at his own university, a major drugmaker, allegations of misconduct, a lawsuit and various investigations. But answers to questions continue to raise more questions, so he has initiated an online petition asking the Minnesota governor to probe his employer. He explains why…The University of Minnesota has turned me into an activist against it. Let me confess right away that this is not a role for which I am naturally suited. I have never staged a protest or addressed a rally. Nor have I ever marched with a sign. On the occasions when I am required to give public lectures, I sweat nervously and display an embarrassing tendency to pause in mid-sentence for uncomfortably long periods. But even I can work up a pretty good head of anger when I see cruelty or injustice, and this is especially true when the injustice is deliberately inflicted and the victim cannot...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...